Turku, Finland – 3 February 2022: DelSiTech Ltd, a Finnish drug delivery technology and development company announced today that Mr. Kristian Rantala has been appointed to its Chief Financial Officer (CFO), effective as of February 7, 2022. Kristian Rantala has over 20 years of experience in all financial management aspects, including financial reporting, company financing, M&A, and tax planning. He has MSc in Economics from Hanken School of Economics, Helsinki, Finland.

Mr. Rantala moves to DelSiTech from a CFO position in a Finnish dry bulk transportation company Powder-Trans. Prior to this position, he was CFO and VP Finance in a Finland-based international biopharmaceutical company Biotie Therapies Corp. In Biotie, Rantala led the finance team responsible for the Nasdaq IPO in the USA.

“We are very pleased to welcome Kristian Rantala to our leadership team,” said Dr. Lasse Leino, DelSiTech Chief Executive Officer. “His deep and extensive experience in leading the financial operations and supporting rapid company growth – also in drug development business – will make a significant impact on DelSiTech’s future. Especially, Mr. Rantala will have a central role in reaching our near-term financial goals.”

“I am thrilled to join DelSiTech, a company whose rapid growth I have followed closely already for several years,” said Mr. Rantala. “I look forward to working with the DelSiTech team to execute company’s exciting growth strategy and bring enhanced value for shareholders.”